UK General Practitioners Skeptical That Artificial Intelligence Could Replace Them

Lindsey Diaz-MacInnis (617) 667-7372 , ldiaz2@bidmc.harvard.edu

DECEMBER 12, 2018

 

BIDMC Research Briefs showcase groundbreaking scientific advances that are transforming medical care.

Survey finds GPs’ views strongly contrast with those of biomedical informaticians who argue that primary care is poised for major disruption

  • Most UK GPs believe that future technology would not be able to perform better than the average GP in key primary care tasks including: diagnostics, referral to other specialists, and the provision of empathic care

  • In contrast, half of respondents believe that future technology would be capable of fully replacing humans in the task of prognostics

BOSTON – Artificial intelligence (AI) is poised to disrupt the world of work. In a UK-wide survey published in the journal PLOS ONE, Charlotte Blease, PhD, Postdoctoral Research Fellow and Fulbright Scholar at Beth Israel Deaconess Medical Center (BIDMC), and colleagues investigated primary care physicians’ views on AI’s looming impact on health professions. When it came to predictions about the future of medicine, British GPs were generally skeptical that they could be entirely replaced by AI.

“To our knowledge this is the first national survey that explores medical professionals' opinions about how AI will impact the future of a medical specialty,” said Blease, who is also a Postdoctoral Research Fellow at Harvard Medical School and University College Dublin. “The results suggest a disconnection between the views of experts in medical AI and practicing physicians: the overwhelming majority of general practitioners were unconvinced about the potential for technology to replace them especially when it comes to empathetic patient care.”

Blease and colleagues asked physicians about the likelihood that future technology would be able to fully replace the average GP in performing six different medical tasks: diagnostics; prognostics; evaluating when to refer patients to specialists; formulating personalized treatment plans for patients; providing empathic care; and updating patient documentation such as medical records.

About half of GPs surveyed believed it likely or very likely that AI would be able to replace them in making patient prognoses in the future. Eighty (80) percent of respondents believed it likely or very likely that future technology would be able to fully undertake duties related to patient documentation, such as updating medical records.

However, the overwhelming majority of UK GPs studied (94%) believed it was unlikely or extremely unlikely that technology will be able to provide empathic care to patients as well as or better than the average GP. Nearly seven in 10 UK GPs surveyed believed that it was unlikely or very unlikely that future technology would be able to outperform the average GP when it came to diagnosing patients; and more than 60 percent of GPs believed it unlikely or very unlikely that technology would ever be able to replace doctors in decisions about when to refer patients to specialists, with a similar number of GPs cynical about replacement when it comes to formulating personal treatment plans for patients.

Against their general skepticism about artificial intelligence, the study found that GPs appeared optimistic that future technology could undertake certain automated tasks, such as paper work. “Overwhelmingly, general practitioners also believed that artificial intelligence could never replace them on empathy – yet this is a skill that does not require special medical expertise,” said Blease. “Our findings raise important questions about how current and future physicians integrate and harness the power of artificial intelligence, which could ultimately improve the delivery of care to patients.”

A link to the study can be found here: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207418.

Co-senior authors included R. B. Davis and C.M. DesRoches as well as T.J. Kaptchuk, all of BIDMC. Other authors included M. H. Bernstein of Brown University; J. Gaab of the University of Basel, Switzerland; J. Kossowsky of the University of Basel, Switzerland and Boston Children’s Hospital; and K. D. Mandl of Harvard Medical School.

This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR002541 and financial contributions from Harvard University and its affiliated academic health care centers; it was also supported by an Irish Research Council-Marie Skłodowska Curie Global Fellowship (CLNE/2017/226) and a grant from the University of Basel, Switzerland. Additional funding: CB was supported by a Fulbright Award. MHB was supported by T32DA016184. The study funders played no role in the study design; writing of the report; or the decision to submit the manuscript for publication. Researchers were independent of influence from study funders.

All authors have completed the ICMJE uniform disclosure form and declare no support from any organization that might have an interest in the submitted work in the previous three years, and no other relationships or activities that could appear to have influenced the submitted work.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.

BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.

BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.